Mina Farrar
Family · Knoxville, TNNPI 1275930380
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,385 of the $21,209 with a category attached, or 82.0%. 54 manufacturers reported payments, led by Neurelis, Inc. at 25.8% of the total. Reporting peaked in 2023 at $6,878 and has fallen 73.6% since, to $1,818 in 2025. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 870 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$5K
- UCB, Inc.$2K
- Biogen$1K
- Neurocrine Biosciences, Inc.$1K
- Eisai Inc.$951
- Bristol Myers Squibb$809
- plus $9K from 48 others
What the payments were for
- Speaking & faculty fees$3,51117%
- Travel & lodging$2301%
- Food & beverage$17,38582%
- Education$820%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,209 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 30 | $42,461 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $28,980 |
| RytaryCarbidopa/Levodopa | 40 | $23,639 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $21,046 |
| Nurtec OdtRimegepant Sulfate | 16 | $19,183 |
| UbrelvyUbrogepant | 11 | $11,159 |
| FycompaPerampanel | 12 | $7,463 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 335 | $4,792 |
| Lacosamide | 69 | $4,578 |
| Ropinirole Hcl | 136 | $3,396 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 59 | $3,233 |
| Pregabalin | 180 | $3,153 |
| Gabapentin | 283 | $2,852 |
| Memantine Hcl | 101 | $2,545 |
| Levetiracetam | 86 | $2,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $2,116 | $42,46130 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil | $651 | $24,04655 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $346 | $21,04617 claims |
| PfizerNurtec Odt | $14 | $19,18316 claims |
| AbbVieUbrelvy | $366 | $11,15911 claims |
| Eisai Inc.Fycompa | $951 | $7,46312 claims |
| Upsher-smith Laboratories LLCTopiramate | $28 | $35827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Knoxville
- Dana WebberKnoxville$499K
- Tiffany SipeKnoxville$87K
- Ashley BonnellKnoxville$49K
- Stacey MaltmanKnoxville$34K
- Katherine JohnsonKnoxville$32K
- Ashley BellKnoxville$22K
- Carol HawkinsKnoxville$22K
- Amy AllenKnoxville$21K
- Sarah HarderKnoxville$19K
- Stacy BrownMt Juliet$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.